vs
ANI PHARMACEUTICALS INC（ANIP）とMativ Holdings, Inc.（MATV）の財務データ比較。上の社名をクリックして会社を切り替えられます
Mativ Holdings, Inc.の直近四半期売上が大きい（$463.1M vs $247.1M、ANI PHARMACEUTICALS INCの約1.9倍）。Mativ Holdings, Inc.の純利益率が高く（21.8% vs 11.1%、差は10.6%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 1.0%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $8.0M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -3.8%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Mativ Holdings, Inc.は世界的な特殊材料メーカーで、高性能先端ポリマー、不織布、ろ過ソリューション、機能性コーティング材料を製造しています。医療、産業、消費財、航空宇宙、エネルギー分野に顧客を持ち、北米、欧州、アジア太平洋地域で事業を展開しています。
ANIP vs MATV — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $463.1M |
| 純利益 | $27.5M | $100.8M |
| 粗利率 | — | 18.8% |
| 営業利益率 | 14.1% | 2.2% |
| 純利益率 | 11.1% | 21.8% |
| 売上前年比 | 29.6% | 1.0% |
| 純利益前年比 | 367.5% | 6620.0% |
| EPS（希薄化後） | $1.14 | $1.87 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $463.1M | ||
| Q3 25 | $227.8M | $513.7M | ||
| Q2 25 | $211.4M | $525.4M | ||
| Q1 25 | $197.1M | $484.8M | ||
| Q4 24 | $190.6M | $458.6M | ||
| Q3 24 | $148.3M | $498.5M | ||
| Q2 24 | $138.0M | $523.8M | ||
| Q1 24 | $137.4M | $500.2M |
| Q4 25 | $27.5M | $100.8M | ||
| Q3 25 | $26.6M | $-3.2M | ||
| Q2 25 | $8.5M | $-9.5M | ||
| Q1 25 | $15.7M | $-425.5M | ||
| Q4 24 | $-10.3M | $1.5M | ||
| Q3 24 | $-24.2M | $-20.8M | ||
| Q2 24 | $-2.3M | $-1.4M | ||
| Q1 24 | $18.2M | $-28.0M |
| Q4 25 | — | 18.8% | ||
| Q3 25 | — | 19.3% | ||
| Q2 25 | — | 19.7% | ||
| Q1 25 | — | 15.0% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 18.8% | ||
| Q2 24 | — | 20.8% | ||
| Q1 24 | — | 16.8% |
| Q4 25 | 14.1% | 2.2% | ||
| Q3 25 | 15.9% | 3.1% | ||
| Q2 25 | 6.6% | 3.8% | ||
| Q1 25 | 13.3% | -88.8% | ||
| Q4 24 | -2.3% | 0.6% | ||
| Q3 24 | -13.8% | 1.4% | ||
| Q2 24 | 3.7% | 2.0% | ||
| Q1 24 | 14.8% | -2.8% |
| Q4 25 | 11.1% | 21.8% | ||
| Q3 25 | 11.7% | -0.6% | ||
| Q2 25 | 4.0% | -1.8% | ||
| Q1 25 | 8.0% | -87.8% | ||
| Q4 24 | -5.4% | 0.3% | ||
| Q3 24 | -16.3% | -4.2% | ||
| Q2 24 | -1.7% | -0.3% | ||
| Q1 24 | 13.2% | -5.6% |
| Q4 25 | $1.14 | $1.87 | ||
| Q3 25 | $1.13 | $-0.06 | ||
| Q2 25 | $0.36 | $-0.18 | ||
| Q1 25 | $0.69 | $-7.82 | ||
| Q4 24 | $-0.45 | $0.03 | ||
| Q3 24 | $-1.27 | $-0.38 | ||
| Q2 24 | $-0.14 | $-0.03 | ||
| Q1 24 | $0.82 | $-0.52 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $84.2M |
| 総負債低いほど良い | — | $1.0B |
| 株主資本純資産 | $540.7M | $498.7M |
| 総資産 | $1.4B | $2.1B |
| 負債/資本比率低いほどレバレッジが低い | — | 2.07× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $84.2M | ||
| Q3 25 | $262.6M | $97.1M | ||
| Q2 25 | $217.8M | $95.6M | ||
| Q1 25 | $149.8M | $84.0M | ||
| Q4 24 | $144.9M | $94.3M | ||
| Q3 24 | $145.0M | $162.2M | ||
| Q2 24 | $240.1M | $133.4M | ||
| Q1 24 | $228.6M | $128.9M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $540.7M | $498.7M | ||
| Q3 25 | $505.8M | $397.4M | ||
| Q2 25 | $436.8M | $416.6M | ||
| Q1 25 | $418.6M | $428.2M | ||
| Q4 24 | $403.7M | $858.5M | ||
| Q3 24 | $405.9M | $882.3M | ||
| Q2 24 | $455.8M | $898.0M | ||
| Q1 24 | $452.0M | $906.9M |
| Q4 25 | $1.4B | $2.1B | ||
| Q3 25 | $1.4B | $2.0B | ||
| Q2 25 | $1.3B | $2.1B | ||
| Q1 25 | $1.3B | $2.1B | ||
| Q4 24 | $1.3B | $2.4B | ||
| Q3 24 | $1.3B | $2.6B | ||
| Q2 24 | $920.8M | $2.6B | ||
| Q1 24 | $914.5M | $2.7B |
| Q4 25 | — | 2.07× | ||
| Q3 25 | — | 2.63× | ||
| Q2 25 | — | 2.66× | ||
| Q1 25 | — | 2.67× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | 1.30× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $19.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $8.0M |
| FCFマージンFCF / 売上 | 11.8% | 1.7% |
| 設備投資強度設備投資 / 売上 | 0.5% | 2.4% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 0.19× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $93.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $19.3M | ||
| Q3 25 | $44.1M | $72.8M | ||
| Q2 25 | $75.8M | $57.6M | ||
| Q1 25 | $35.0M | $-15.9M | ||
| Q4 24 | $15.9M | $24.1M | ||
| Q3 24 | $12.5M | $37.6M | ||
| Q2 24 | $17.4M | $46.1M | ||
| Q1 24 | $18.3M | $-13.0M |
| Q4 25 | $29.1M | $8.0M | ||
| Q3 25 | $38.0M | $66.7M | ||
| Q2 25 | $71.8M | $48.9M | ||
| Q1 25 | $32.5M | $-29.8M | ||
| Q4 24 | $13.5M | $2.0M | ||
| Q3 24 | $7.7M | $25.5M | ||
| Q2 24 | $13.0M | $37.4M | ||
| Q1 24 | $13.7M | $-25.1M |
| Q4 25 | 11.8% | 1.7% | ||
| Q3 25 | 16.7% | 13.0% | ||
| Q2 25 | 34.0% | 9.3% | ||
| Q1 25 | 16.5% | -6.1% | ||
| Q4 24 | 7.1% | 0.4% | ||
| Q3 24 | 5.2% | 5.1% | ||
| Q2 24 | 9.4% | 7.1% | ||
| Q1 24 | 10.0% | -5.0% |
| Q4 25 | 0.5% | 2.4% | ||
| Q3 25 | 2.7% | 1.2% | ||
| Q2 25 | 1.9% | 1.7% | ||
| Q1 25 | 1.3% | 2.9% | ||
| Q4 24 | 1.3% | 4.8% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 3.2% | 1.7% | ||
| Q1 24 | 3.3% | 2.4% |
| Q4 25 | 1.10× | 0.19× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 16.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
